“I've noticed you *keep* mentioning a pullback. Why is that?”

Because it’s inevitable. I’ve been in biotechs a long time and they always pullback, regardless of how valuable the company *should* be. I’m long CYDY, but I understand the process that’s going to take place before leronlimab realizes it’s potential, both scientifically and monetarily. And that process will include pullbacks, consolidation, etc., which is healthy.